Fujian Cancer Hospital

Fujian 350015

2 studies enrolling now · 4 studies all time

What they study most

Breast Adenocarcinoma, Breast Cancer, Cervical Cancer, Endometrial Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Fallopian Tube Cancer, High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Locally Advanced or Unresectable Metastatic Breast Cancer, Mesothelioma, Non-small Cell Lung Cancer

Studies at this site

• Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) — Recruiting now
• Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer — Recruiting now
• Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy — Running, not enrolling
• A Study of ADRX-0706 in Select Advanced Solid Tumors — Running, not enrolling